Skip to main navigation Skip to search Skip to main content

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil

  • Ron Ram
  • , Corina Herscovici
  • , Dikla Dahan
  • , Moshe Israeli
  • , Juliet Dreyer
  • , Anat Peck
  • , Ofer Shpilberg
  • , Moshe Yeshurun

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.

Original languageEnglish
Pages (from-to)913-917
Number of pages5
JournalLeukemia Research
Volume38
Issue number8
DOIs
StatePublished - 1 Jan 2014
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • GVHD
  • Hematopoietic cell transplantation
  • MMF
  • Methotrexate

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil'. Together they form a unique fingerprint.

Cite this